Ligand Pharmaceuticals | LGND - Loan Capital

Stock Price
197.79
Daily Change
1.62 0.83%
Monthly
3.98%
Yearly
61.82%
Q1 Forecast
178.28

Ligand Pharmaceuticals reported $445.49M in Loan Capital for its fiscal quarter ending in September of 2025.





Loan Capital Change Date
Agenus USD 23.6M 448K Sep/2025
Amgen USD 50B 2.43B Dec/2025
Anika Therapeutics USD 0 0 Mar/2025
Arrowhead Research USD 538.1M 323.22M Dec/2025
Baxter International USD 9.47B 726M Dec/2025
Bristol-Myers Squibb USD 42.85B 1.62B Dec/2025
Eli Lilly USD 40.87B 5.6M Dec/2025
Enanta Pharmaceuticals USD 0 0 Dec/2024
Enviri Corporation USD 1.5B 17.9M Sep/2025
Gilead Sciences USD 22.14B 5M Sep/2025
GlaxoSmithKline GBP 14.71B 186M Dec/2025
Glaxosmithkline GBP 20.02B 4.72B Sep/2025
Heron Therapeutics USD 149.65M 157K Sep/2024
Insmed USD 540.96M 1.24M Dec/2025
Intrexon USD 0 198.67M Jun/2024
Ionis Pharmaceuticals USD 1.9B 1.87B Dec/2025
Karyopharm Therapeutics USD -0.93 0.67 Dec/2024
Ligand Pharmaceuticals USD 445.49M 445.44M Sep/2025
MacroGenics USD 70.26M 4K Sep/2025
Merck USD 39.97B 6B Sep/2025
Pacira USD 372.19M 4.53M Dec/2025
Pfizer USD 57.41B 93M Sep/2025
Rigel Pharmaceuticals USD 0 0 Sep/2024
Sangamo BioSciences USD 0 0 Jun/2022
Veracyte USD 0 0 Mar/2025